// LAUNCH dashboard data file.
// Everything after the assignment on the marker line below must be STRICT JSON
// (double quotes, no comments, no trailing commas) — run
// `node scripts/validate-data.js` after every edit; it refuses anything malformed.
//
// Provenance fields used throughout:
//   "source"              where the figure comes from (public source, citable)
//   "asOf"                date the value was last verified (YYYY-MM-DD)
//   "confirmedInWriting"  manufacturer confirmed release of this figure in writing
//
// meta.dataStatus: "illustrative" | "draft" | "live"
//   draft = compiled from public sources, pending LAUNCH team verification
//           and manufacturer written confirmation. Unknown values are "TBC" —
//           never estimated.
  //
  // stageColumns: how the stages above are grouped into display columns.
  // Most columns hold one stage index; a column that lists more than one
  // (currently [2, 3] — WHO recommendation and WHO PQ listing) is a
  // *parallel* pair: two independent WHO approvals shown side by side in one
  // column, with no arrow or implied order between them. WHO runs these as
  // separate tracks and (per LAUNCH's 2026 review) wants them read that way;
  // drawing them strictly in sequence had been quietly endorsing the opposite.
  // Flattened in order, stageColumns must equal every index in "stages"
  // exactly once, ascending — scripts/validate-data.js enforces this.
  //
  // stageInfo: one plain-language explainer per stage, same order as "stages".
  // Shown in the panel that opens when a step on the pathway strip is clicked
  // (what happens there, who decides, why it can stall, where to check it).
  // Written from docs/domain-primer.md section 2; draft wording, needs LAUNCH
  // sign-off. Optional: without it the panel shows only where each medicine is.
  //
  // yardstick: how long each stage is expected to take, in years, same order
  // as "stages" (null = not measured), and "wholeYears" for the whole journey
  // to routine use. "basis" is "published" for a timeline someone publishes
  // (country registration) or "estimate" for LAUNCH's own working estimate,
  // still to be agreed. The page compares these with the stage dates: the
  // badge in the medicines table, the box at the top of an open row and the
  // "Time taken" table. Optional: without it none of the three is shown.
  // See docs/jackson/yardstick.md.
  // Since 15 Oct 2026 the page shows only the expected time under each stage
  // on the pathway strip: the three comparisons are hidden at the partners'
  // request until the benchmark method is agreed (YARD_COMPARE in the page).
  //
window.LAUNCH_DATA =
{
  "meta": {
    "lastUpdated": "2026-10-19",
    "dataStatus": "draft",
    "host": "RBM Partnership to End Malaria"
  },
  "stages": [
    "R&D and Clinical",
    "Stringent Regulatory Approval (SRA)",
    "WHO recommendation",
    "WHO PQ listing",
    "Country registration",
    "National policy adoption",
    "Procurement (public channels)",
    "In-country delivery"
  ],
  "stageColumns": [
    { "stages": [0] },
    { "stages": [1] },
    { "stages": [2, 3] },
    { "stages": [4] },
    { "stages": [5] },
    { "stages": [6] },
    { "stages": [7] }
  ],
  "stageInfo": [
    { "what": "Lab discovery, then three rounds of human trials: first for safety, then for the right dose, then large efficacy trials across several countries. The trials alone usually take 3 to 6 years.", "who": "The manufacturer, often with a product development partnership such as MMV", "stall": "Recruiting enough patients, and running trial sites in several countries.", "source": "Trial registries and manufacturer announcements" },
    { "what": "A stringent regulator reviews the full evidence on quality, safety and effectiveness. For malaria medicines this is usually the European Medicines Agency (EMA) EU-M4all procedure (formerly Article 58), which covers medicines meant for use outside Europe. Every later step builds on this opinion. Health authority review status is generally not public, so this step changes only when a regulator or the manufacturer announces an outcome.", "who": "EMA, or another stringent regulator such as the US FDA", "stall": "Preparing the full dossier, then waiting out the review.", "source": "EMA registers" },
    { "what": "A WHO expert group weighs clinical evidence and decides whether the medicine is included in WHO guidelines for malaria.", "who": "WHO Department of Malaria and Neglected Tropical Diseases (MNT) and its Guidelines Development Group", "stall": "The group meets on its own calendar, so the timing is hard to predict.", "source": "WHO Guidelines for malaria" },
    { "what": "A separate WHO check of quality and manufacturing, including factory inspections. Prequalification supports eligibility for purchase under the quality assurance and procurement policies of UN agencies and major funders such as the Global Fund; specific policies and exceptions may differ. Manufacturers are invited to apply through a WHO Expression of Interest (EOI).", "who": "WHO Prequalification Team", "stall": "Waiting for an invitation round, then for inspections.", "source": "WHO prequalification list and EOI" },
    { "what": "Each country's own regulator licenses the medicine before it can be sold or used there, usually one country at a time. Regional routes, such as the African Medicines Agency and WHO's collaborative registration (about 90 working days), are intended to speed this up.", "who": "National medicines regulators", "stall": "Going country by country, each with its own queue.", "source": "National medicines registers" },
    { "what": "Ministries of Health include the medicine in national treatment guidelines. These decide what health workers prescribe and what the public sector buys.", "who": "Ministries of Health and national malaria programmes", "stall": "National guideline committees meet rarely and follow their own schedules.", "source": "National treatment guidelines" },
    { "what": "Public funders, such as the Global Fund, other donors and national governments, run tenders, agree reference prices and forecast demand. A medicine can be recommended, registered and in the guidelines and still be barely bought. This step covers public channels only: the figures shown are Global Fund-financed procurement. Private commercial channels are not included.", "who": "The Global Fund, other donors, UNICEF and national governments", "stall": "Financing cycles. Global Fund grants, for example, run for three years.", "source": "Global Fund price and quality reporting" },
    { "what": "Supply from port to health facility, health-worker training, and pharmacovigilance once the medicine is in use.", "who": "Governments and implementing partners", "stall": "Supply chain readiness and health-worker training.", "source": "Manufacturer and programme communications" }
  ],
  "yardstick": {
    "wholeYears": 8,
    "expected": [
      null,
      null,
      { "years": 2, "basis": "estimate" },
      { "years": 1.5, "basis": "estimate" },
      { "years": 2, "basis": "published" },
      { "years": 2, "basis": "estimate" },
      { "years": 2, "basis": "estimate" },
      { "years": 3, "basis": "estimate" }
    ]
  },
  "glossary": {
    "ACT": "Artemisinin-based combination therapy — the standard class of malaria treatments pairing an artemisinin derivative with a longer-acting partner drug.",
    "SRA": "Stringent Regulatory Authority — the older WHO term for an advanced regulator such as EMA or the US FDA. WHO is replacing it with WHO-Listed Authorities (WLA), regulators assessed against WHO's performance indicators; existing SRAs are treated as WHO-listed during the transition.",
    "WLA": "WHO-Listed Authority — a regulator assessed by WHO as operating at an advanced level.",
    "EU-M4all": "EU-Medicines for all, formerly the Article 58 procedure — EMA's scientific opinion on high-priority medicines intended for markets outside the EU.",
    "GDG": "Guidelines Development Group — the WHO expert group that reviews evidence and formulates treatment recommendations.",
    "PQ": "WHO prequalification — the quality, safety and efficacy assessment whose outcome, a listing on the WHO prequalified-products list, supports eligibility under the quality assurance (QA) and procurement policies of UN agencies and major funders; specific policies and exceptions may differ.",
    "MFT": "Multiple first-line therapies — the deliberate, managed use of two or more effective ACTs in a population for treatment of uncomplicated malaria, either simultaneously or in rotation.",
    "EOI": "Expression of Interest — the WHO prequalification invitation list; a product must be on it before a PQ dossier can be assessed.",
    "AMA": "African Medicines Agency — the African Union's continental medicines agency, based in Kigali, set up to harmonise regulation across the member states that have ratified its treaty and to evaluate selected priority products. National regulators still grant marketing authorisation.",
    "PMI": "U.S. President's Malaria Initiative — a major bilateral funder and procurer of malaria commodities.",
    "MMV": "Medicines for Malaria Venture — product development partnership behind several antimalarials.",
    "PQR": "Price & Quality Reporting — the Global Fund database of procurement transactions (volumes and prices).",
    "GMP": "Good Manufacturing Practice — quality standard verified by inspection of manufacturing sites."
  },
  "changelog": [
    { "date": "2026-10-19", "product": "All", "change": "Medicine cards: every claim checked against its source (partner feedback, row 51; docs/claims-audit-2026-10.md). Where the partners' own wording from the 15 Oct email is already live (the ALAQ, ASPY and DHA–PPQ use cases and ASPY's country counts), it is kept. GanLum: the Phase III result gives its comparator (97.4% vs 94.0% for Coartem) and says it is company-reported, not yet peer-reviewed; access, adoption and research lines reworded. ALAQ: the partnership is FD-TACT (GHIT Fund, with MMV and Marubeni), not DeTACT, in the developer, access and research lines; the R&D stage cites the trial record (NCT05951595, started 11 Sep 2025); \"child-friendly\" removed. ASPY: the 2025 pregnancy label change stated as it is (2nd and 3rd trimesters when the benefit outweighs the risk) and dated as EMA records it (opinion 5 Jun 2025, product information updated 6 Aug 2025; MMV gives 31 Jul 2025); liver-disease contraindication added. DHA–PPQ: \"No single-source dependency\" and \"Established API supply chains\" removed (WHO PQ records list one dihydroartemisinin source for 8 of 9 presentations); ECG line corrected. Procurement step notes and an ASPY milestone give transactions instead of pack totals.", "plain": "We checked every claim on the medicine pages against its source. Claims that no published result supports were removed or reworded, and some statements were corrected: most DHA–PPQ presentations rely on a single supplier of the main ingredient, ASPY's 2025 pregnancy label covers the second and third trimesters, and the ALAQ development partnership is now named correctly." },
    { "date": "2026-10-19", "product": "GanLum", "change": "Stringent Regulatory Approval (SRA) stage: status changed from In progress to Not started, shown with the line \"Regulatory submission in preparation\" (partner feedback, 15 Oct 2026). Novartis said in Nov 2025 that it would seek approval, first through Swissmedic; no filing had been announced as of 15 Oct 2026. Use case reworded to \"Non-artemisinin combination in late-stage development. Novartis presents it as having the potential to combat antimalarial drug resistance; LAUNCH tracks it as a candidate for settings with artemisinin partial resistance and for multiple first-line therapy (MFT) strategies.\", which removes the unattributed claims \"kills resistant parasites and blocks transmission\" and the \"first major innovation\" quote; \"no separate paediatric development needed\" removed from access.", "plain": "The regulatory approval step now reads \"Not started\": a submission is being prepared, but none has been announced. We also removed some claims that were not attributed to a source." },
    { "date": "2026-10-19", "product": "All", "change": "Glossary, from partner feedback (15 Oct 2026): MFT, SRA, PQ and AMA definitions updated; \"Article 58\" is now listed as EU-M4all, formerly the Article 58 procedure. The SRA and WHO PQ step explanations follow (EU-M4all; prequalification supports eligibility under the quality assurance and procurement policies of UN agencies and major funders). Medicines without a recorded barrier now read \"No publicly documented barrier identified\". Procurement (ASPY, DHA–PPQ): the headline is now transactions and value (68 transactions · US$14.5m; 234 transactions · US$41.5m) instead of a packs total that added packs of 3 to 225 tablets as one each; packs are listed by presentation, with treatment courses estimated only where the Global Fund's product name states the tablets per course (DHA–PPQ: 24,223,797 courses from 8,114,772 of 11,493,039 packs; ASPY: not estimated). The \"Global Fund 100%\" bar is replaced by a sentence saying the figures are Global Fund PQR transactions only, not total global procurement. No figure in the PQR extract changed.", "plain": "We updated several definitions in the glossary, including multiple first-line therapies (MFT) and WHO prequalification, to match current WHO and EMA terminology. Procurement is now shown as transactions and value, with packs listed by presentation and treatment courses only where they can be counted; the figures cover Global Fund-recorded purchases only." },
    { "date": "2026-10-19", "product": "All", "change": "Illustrated journey dashboard, from partner feedback (15 Oct sheet). The medicines table's \"On pathway\" column (years since a medicine's first dated milestone, with no end) is replaced by \"Access\": Market Access, reached when every stage up to WHO recommendation and WHO PQ listing is complete, then Country Access, counted in years from that point until registration, national policy adoption, procurement in significant volumes and in-country delivery are all complete. ASPY: market access reached in 2022, 4 years in country access so far (was \"14 years\"). DHA–PPQ: 2015 and 11 years (was \"16 years\"). GanLum and ALAQ: market access not yet reached. The explanation of \"Delayed\" now says it is LAUNCH's judgement from public evidence that a medicine's current stage has stalled, with the reason given as the main barrier, not a comparison with a set deadline. A new \"About LAUNCH\" section gives the initiative's purpose, why it follows these four medicines, that tracking a medicine is not an endorsement, and that the scope may expand. No stage data changed.", "plain": "The medicines table now shows two milestones instead of one open-ended count: the year a medicine reached market access (recommended and prequalified by WHO), and how long it has been moving towards access in countries since then. We also explain what \"Delayed\" means, and a new About LAUNCH section explains why the dashboard follows these four medicines." },
    { "date": "2026-10-19", "product": "All", "change": "Citations on individual claims (15 Oct feedback, Sources & References). Every stage, milestone and procurement figure that names a source now carries \"sources\": ids in data/sources.js, shown on the page as links to each public reference where the claim is. 14 references were added to the Sources list, each checked on 19 Oct 2026: MMV's GanLum Phase III release, the KALUMA and FD-TACT trial records, WHO's 24th malaria EOI, the 2025 ALAQ dosing paper, WHO's 2025 child malaria medicine priorities, the GHIT Fund ALAQ project, MMV's Pyramax and Eurartesim pages and its Pyramax pregnancy news, EMA's Pyramax opinion and Eurartesim authorisation, WHO's 2010 treatment guidelines, and WHO's Eurartesim assessment report. Wording corrected to what those references say: ALAQ's ~2027 SRA and WHO PQ targets are removed (no public source; both now TBC); \"successor to the DeTACT programme\" is removed; KALUMA ran at 33 sites (was 34); the 24th malaria EOI was updated on 27 Feb 2026; ASPY's pregnancy label changed on 31 Jul 2025 (was \"announced\"). No status changed.", "plain": "Each stage and milestone now links to the public source behind it, and we added 14 references to the Sources list. We removed ALAQ's target dates for approval and WHO prequalification, which no public source confirms, and corrected a few details to match the sources. No statuses changed." },
    { "date": "2026-10-15", "product": "All", "change": "Wording from the partners' feedback email (15 Oct 2026). WHO's department is given its new name, \"Department of Malaria and Neglected Tropical Diseases (MNT)\", formed when WHO merged its Global Malaria Programme and Global NTD Programme: in the WHO recommendation step (was \"WHO Malaria and Neglected Tropical Diseases Department\") and as the publisher of two sources, the WHO Malaria Threats Map and the WHO MFT implementation guide (was \"Global Malaria Programme\"). Country counts now come from the country access map's own list, each country counted once at the furthest stage it has reached: detail.country for ASPY is 2 registered, 7 in national guidelines, 4 in MFT plans (was 13, 11, 4, which counted every country on the map as registered and in guidelines); DHA–PPQ is 2, 9, 4 (was 15, 13, 4). The page adds how many countries a national register confirms (ASPY 5, DHA–PPQ 6). National guideline inclusion is restated from the same list: ASPY \"7 countries, plus 4 with MFT plans\" (was \"Ghana only — 1 country confirmed\"), DHA–PPQ \"9 countries, plus 4 with MFT plans\" (was \"Counts TBC\"); DHA–PPQ registration no longer says \"Registered widely\" but names the six register-confirmed countries. No status or date changed. The yardstick's comparisons are hidden until its benchmark method is agreed: the page no longer shows the years-late badges (ASPY 6, DHA–PPQ 8), the box at the top of an open row or the Time taken view with its Variance column. The expected time under each stage on the pathway strip stays, and the yardstick block is unchanged. ALAQ's use case now reads \"Triple artemisinin-based combination therapy in clinical development. Its potential future role may include use within treatment-diversification or MFT strategies, subject to clinical results, regulatory assessment, WHO recommendations and country decisions.\" (was \"Triple ACT to protect artemisinin partner drugs — MFT component and first-line option where artemisinin partial resistance is confirmed.\"). ASPY's use case now reads \"WHO-recommended ACT with verified registration and adoption varying by country. LAUNCH is validating country-level registration, guideline inclusion, MFT positioning, procurement and routine-use information.\" (was \"First-line diversification / MFT component; paediatric granules available; label includes pregnant women (2025 update).\"; the paediatric granules stay in its access list and the 2025 pregnancy label in its milestones), and its active ingredients are written artesunate–pyronaridine throughout (was also pyronaridine–artesunate, as in its subtitle). DHA–PPQ: the use case follows the email: its first sentence as written, then \"Chemoprevention and mass drug administration are separate uses, each with its own indications, formulations, evidence and policy pathway.\" (was \"MFT rotation partner; mass drug administration and chemoprevention niches; once-daily dosing.\"); the research question names simultaneous deployment and cycling as well as rotation; routine use reads \"Routine use and procurement vary substantially between countries\" (was \"concentrated in Southeast Asia and chemoprevention niches\"); the 0.9–4.5% names its denominator, the value of all antimalarial medicines the Global Fund ordered each year in 2022–24 (PQR: 4.4%, 0.9%, 4.5%), in the flag, the barrier and the procurement note, which also says orders go back to 2008 while the timeline counts from WHO PQ in 2015; the register row reads \"Tanzania: 10 registered presentations, all compliant · Nigeria: 47 registered presentations, 25 active, 22 lapsed\" (was \"TZA 10 compliant · NGA 26/47 active\": the 26 counted the Pyramax granules registration, which is ASPY), from the extracts of 31 Aug 2026.", "plain": "We updated the name of WHO's malaria department to the Department of Malaria and Neglected Tropical Diseases (MNT). The country counts for ASPY and DHA–PPQ now match the country access map, and we show how many countries a national medicines register confirms. We removed the years-late figures until the way they are worked out is agreed; the expected time for each stage stays. ALAQ's description now says it is still in clinical development and that its future role depends on trial results, regulators, WHO and countries. ASPY's description now says that registration and adoption vary by country and that LAUNCH is checking them country by country. For DHA–PPQ we explain what the 0.9–4.5% is a share of, describe its uses more carefully, and corrected Nigeria's count of active registrations from 26 to 25. No dates or statuses changed." },
    { "date": "2026-10-15", "product": "All", "change": "Illustrated journey dashboard, wording from partner feedback (15 Oct 2026). The first two steps are renamed \"R&D and Clinical\" (was \"R&D & clinical\") and \"Stringent Regulatory Approval (SRA)\" (was \"Regulatory approval (SRA)\"). Step explanations reworded: WHO recommendation (shorter; decided by the WHO Malaria and Neglected Tropical Diseases Department, which the Global Malaria Programme merged into in 2025, and its Guidelines Development Group); WHO PQ listing; country registration; national policy adoption (Ministries of Health); procurement (public funders: the Global Fund, other donors and national governments; private commercial channels excluded; PMI no longer named); in-country delivery (pharmacovigilance). \"Who decides\" lines lose their final full stop. No status, date or figure changed.", "plain": "We reworded the explanations of the steps on the pathway after partner feedback, and renamed the first two steps \"R&D and Clinical\" and \"Stringent Regulatory Approval (SRA)\". No dates, statuses or figures changed." },
    { "date": "2026-10-08", "product": "All", "change": "Illustrated journey dashboard: a yardstick compares how long each stage is expected to take with how long it has taken. New \"yardstick\" block in this file: expected years per stage (WHO recommendation 2, WHO PQ listing 1.5, country registration 2, national policy adoption 2, procurement 2, in-country delivery 3) and 8 for the whole journey. Country registration follows a published timeline; the others are LAUNCH working estimates, still to be agreed. Shown as a badge under On pathway (ASPY 6 yrs late, DHA–PPQ 8 yrs late, GanLum and ALAQ not approved yet), a box at the top of an open row, and a new Time taken view. No stage data changed.", "plain": "Each approved medicine now shows how many years late it is against the time each step is expected to take, with a new Time taken table. The expected times are LAUNCH's working estimates, except country registration, and are still to be agreed." },
    { "date": "2026-10-06", "product": "All", "change": "Country access map: the illustrative country lists for ASPY and DHA–PPQ are replaced with verified ones. A country is shown only when a national medicines regulator's register, a WHO publication or a peer-reviewed paper supports its stage; every other country shows No data. ASPY: 13 countries (Nigeria, Rwanda, Burkina Faso and Kenya in MFT plans; Ghana, Viet Nam, DR Congo, Cameroon, Thailand, Republic of Korea and South Sudan in national guidelines; Tanzania and Zambia registered). DHA–PPQ: 15 countries (Nigeria, Rwanda, Burkina Faso and Kenya in MFT plans; Tanzania, Viet Nam, Thailand, Indonesia, Ghana, Angola, Cameroon, Gabon and Papua New Guinea in national guidelines; Zambia and Zimbabwe registered). Removed for lack of such a source: Cambodia, Côte d'Ivoire, Uganda, Mozambique, Senegal, Mali and Myanmar (ASPY); Cambodia, Mozambique, Senegal, Myanmar, Lao PDR, China and India (DHA–PPQ). Each entry now cites its sources and the date checked. New sources: the Zambia, Zimbabwe, Viet Nam and Rwanda registers (fetched monthly), the WHO national drug policy table, the WHO MFT implementation guide, and three peer-reviewed MFT papers (Rwanda, Burkina Faso, Kenya). The country access figures in each medicine's details now count the same lists, each stage including the later ones as the map does: ASPY 13 registered or further, 11 in national guidelines or further, 4 in MFT plans; DHA–PPQ 15, 13 and 4. ASPY's \"25+ countries\" registration claim, which came from MMV, is replaced by the five national registers that confirm it (Nigeria, Rwanda, Tanzania, Viet Nam, Zambia).", "plain": "The country access map now shows only countries we can back with an official or peer-reviewed source. Some countries moved stage, some were added, and those we could not confirm now show No data. New sources include four national medicine registers and WHO's guide to using several first-line treatments. The country counts in each medicine's details now match the map." },
    { "date": "2026-10-02", "product": "All", "change": "Illustrated journey dashboard, wording changes from reviewer feedback. Price: the per-medicine price card is removed (the price field stays in the data for the other pages). Procurement: the step is now \"Procurement (public channels)\" and says it covers Global Fund-financed procurement only. Regulatory approval: the step and the page footer say health-authority review status is generally not public. GanLum: manufacturer and research lead now read \"Novartis\", the line \"Co-developed with MMV under access-oriented partnership\" is removed, and the required acknowledgement (new `acknowledgement` field) is shown in the medicine's details. A disclaimer is added to the footer and linked from the draft banner.", "plain": "We changed some wording after reviewer feedback. The price card is gone, the procurement step is labelled as public channels only, and the page now says that health-authority review progress is usually not public. GanLum now credits Novartis as its developer, with the required acknowledgement of its funders, and the page has a disclaimer." },
    { "date": "2026-10-01", "product": "All", "change": "Illustrated journey dashboard: the three WHO study-result layers (treatment failure, delayed parasite clearance, molecular markers of drug resistance) were removed from the country access map, together with their data files and sourcing. Drug-resistance results are no longer reproduced here; the page links to the WHO Malaria Threats Map instead. The map's controls were also reorganised: access stages and MFT policy groups are now tickable filters in the left rail, replacing the MFT switch, and the legend under the map lists only what is ticked. The Detail panel is now an overview dashboard with a country finder, and every country on the map opens its own page for the selected medicine. The 5 Sep 2026 entry below records when the layers were added.", "plain": "We removed the drug-resistance results from the map. For that information, the page now points to the WHO Malaria Threats Map. The map's filters and legend have been tidied up, and you can now click any country to see its page." },
    { "date": "2026-09-10", "product": "All", "change": "Terminology: the two product `flag` sentences now say \"access barrier\" rather than \"bottleneck\", matching the illustrated journey dashboard's summary strip and legend. Client request — the programme is about accelerating access, so the blocking stage is named as a barrier to overcome rather than as a bottleneck. Wording only; no status, date or figure changed.", "plain": "We now call a blocked step an \"access barrier\" instead of a \"bottleneck\". Only the wording changed — no figures or dates were altered." },
    { "date": "2026-09-08", "product": "ASPY", "change": "First confirmed national guideline adoption recorded: Ghana introduced artesunate-pyronaridine as an alternate first-line ACT in 2022 (alongside AS-AQ and AL), per a peer-reviewed therapeutic-efficacy study (Ghana 2023 fieldwork, published 2026). National policy adoption stage remains 'late' — Ghana is the only confirmed country so far against WHO's 2022 strong recommendation. Procurement stage dates for ASPY (since 2018) and DHA–PPQ (since 2008) added — both years were already cited in the Global Fund PQR figures elsewhere in this file but had not been carried into the stage `date` field.", "plain": "We found a real example of a country acting on the World Health Organization's advice: Ghana added this medicine as a backup first-choice treatment in 2022. It's still the only country confirmed to have done so. We also recorded the years Global Fund purchasing began for both underused medicines (2018 and 2008)." },
    { "date": "2026-09-05", "product": "All", "change": "Illustrated journey dashboard: the country access map gained a WHO drug-resistance overlay. Treatment-failure results from the WHO Malaria Threat Maps (therapeutic efficacy studies, extract 5 Sep 2026) are drawn as dots over the access shading, with their own provenance line and their own tooltip. All five Plasmodium species and studies of every size are included, selectable by drug and species; pairings WHO has no data for are disabled rather than shown empty. Each dot is the most recent study year for that country, averaged across that year's sites and weighted by patient numbers — click a dot for every underlying study. The access layer remains illustrative, so the two readings are presented separately and not combined." },
    { "date": "2026-08-25", "product": "All", "change": "Version 2 merged: the collected-data updates reviewed in the /v2/ preview (Global Fund PQR volumes, WHO PQ listings, EMA dates, trial-registry records, Nigeria + Tanzania register verification, sourced fact corrections) are now the live draft dataset. The preview edition is retired.", "plain": "Everything we checked during the August review is now part of the main dataset. The separate preview version has been retired." },
    { "date": "2026-08-23", "product": "DHA–PPQ", "change": "Nigeria and Tanzania registrations verified against the national registers: TZA 10 presentations across four manufacturers (all compliant); NGA 47 presentations but only 26 Active — 22 lapsed, a registration-maintenance signal.", "plain": "We checked Nigeria's and Tanzania's official medicine registers. Tanzania lists 10 approved versions of this medicine, all up to date. Nigeria lists 47, but only 26 are still active — 22 have expired and would need renewing." },
    { "date": "2026-08-23", "product": "ASPY", "change": "Nigeria and Tanzania registrations verified against the national registers: TZA 2 (TMDA, 2022), NGA 1 (Greenbook granules, approved Feb 2024). The NGA/TZA registered-level map entries are now register-verified.", "plain": "We checked the official medicine registers: Tanzania approved this medicine in 2022, and Nigeria approved a version for children in February 2024. Both are now confirmed on the map." },
    { "date": "2026-08-23", "product": "DHA–PPQ", "change": "WHO guideline recommendation year corrected to 2010 (second-edition treatment guidelines; reaffirmed 2015) — previously shown as 2015.", "plain": "We corrected the year the World Health Organization first recommended this medicine. It was 2010, not 2015." },
    { "date": "2026-08-23", "product": "ALAQ", "change": "Co-formulated pivotal Phase III renamed to FD-TACT (successor to the DeTACT programme); unverified 'taste-masked' wording replaced with the sourced 'child-friendly dispersible'.", "plain": "We updated the name of the main trial and reworded how we describe the medicine, so both match what the published sources actually say." },
    { "date": "2026-08-23", "product": "GanLum", "change": "Use-case wording aligned with the sourced Novartis claim (first major innovation in malaria treatment since ACTs were introduced 25+ years ago).", "plain": "We reworded how we describe this medicine to match the manufacturer's own words: the first major change in malaria treatment in more than 25 years." },
    { "date": "2026-08-23", "product": "All", "change": "Version 2 preview: first collected-data updates from the public-source staging layer (Global Fund PQR extract 23 Aug 2026, WHO PQ lists, EMA EU-M4all table, ClinicalTrials.gov).", "plain": "First batch of updates drawn from public databases — Global Fund purchasing records, World Health Organization approval lists, European medicines records and clinical trial registries." },
    { "date": "2026-08-23", "product": "DHA–PPQ", "change": "Global Fund volumes filled from PQR: 11.5m packs / US$41.5m since 2008; 0.9–4.5% of Global Fund antimalarial spend 2022–24 with a sharp 2025 uptick (US$15.3m). Nine PQ'd presentations across Alfasigma, Guilin and Beijing Holley (2015–2023) recorded.", "plain": "Purchasing figures added: the Global Fund has bought 11.5 million packs (US$41.5m) since 2008, with a sharp rise in 2025. Nine versions of the medicine have passed World Health Organization quality checks." },
    { "date": "2026-08-23", "product": "ASPY", "change": "Global Fund volumes filled from PQR: 940k packs / US$14.5m since 2018, with US$11.6m of it in 2025 (Uganda, Burkina Faso). EMA opinion outcome date 5 Jun 2025 recorded from the EU-M4all table.", "plain": "Purchasing figures added: the Global Fund has bought 940,000 packs (US$14.5m) since 2018, most of it in 2025 for Uganda and Burkina Faso. The European medicines decision date is now recorded." },
    { "date": "2026-08-23", "product": "GanLum", "change": "KALUMA registry record (NCT05842954) added: trial completed 25 Nov 2025, 1,720 participants (registry actual).", "plain": "The main trial finished on 25 November 2025 with 1,720 participants — now confirmed from the public trial registry." },
    { "date": "2026-08-15", "product": "All", "change": "Added MMV-style pipeline poster view (pipeline.html) placing each product in its development phase.", "plain": "Added a poster view showing where each medicine sits in development." },
    { "date": "2026-08-15", "product": "All", "change": "Added country access map (illustrative until verified), cross-product pathway timing chart, embeddable product widget, RSS update feed and automatic data-history snapshots.", "plain": "Added a country map, a chart of how long each step takes, a shareable widget, an updates feed and automatic snapshots of the data." },
    { "date": "2026-08-14", "product": "ASPY", "change": "Renamed from Pyramax to ASPY (pyronaridine–artesunate); trade name retained in the subtitle.", "plain": "Renamed from Pyramax to ASPY. The brand name still appears underneath." },
    { "date": "2026-08-14", "product": "All", "change": "Added glossary tooltips, CSV download, print view and pathway timing (time between gates) for marketed products.", "plain": "Added plain-language definitions, a download button, a print view, and the time taken between steps." },
    { "date": "2026-08-14", "product": "GanLum", "change": "Phase III (KALUMA) marked complete — primary endpoint met, announced 12 Nov 2025; regulatory submission preparation now in progress.", "plain": "The main trial succeeded, announced on 12 November 2025. Work on the application for approval has now begun." },
    { "date": "2026-08-14", "product": "ASPY", "change": "EMA Article 58 date corrected to 2012; July 2025 pregnancy label update added to milestones.", "plain": "Corrected a European approval date to 2012, and added the July 2025 update to the medicine's label for use in pregnancy." },
    { "date": "2026-08-14", "product": "DHA–PPQ", "change": "Eurartesim WHO PQ requalification (Jan 2025) recorded; unknown counts set to TBC pending verification.", "plain": "Recorded that Eurartesim passed its World Health Organization quality re-check in January 2025. Figures we cannot yet confirm are shown as TBC." },
    { "date": "2026-08-14", "product": "All", "change": "Dashboard moved from illustrative placeholders to draft public-source data. Prices and volumes shown as TBC until confirmed.", "plain": "The dashboard moved from placeholder examples to real information gathered from public sources. Prices and volumes show as TBC until they are confirmed." }
  ],
  "products": [
    {
      "id": "ganlum",
      "name": "GanLum",
      "inn": "Ganaplacide–lumefantrine (KLU156)",
      "manufacturer": "Novartis",
      "acknowledgement": "Developed by Novartis with the scientific and financial support of MMV, and within the framework of the WANECAM2 consortium, funded by the European & Developing Countries Clinical Trials Partnership Programme supported by the European Union, with co-funding from the German Aerospace Center and the UK Department of Health and Social Care.",
      "class": "pipeline",
      "classLabel": "Pipeline · new chemical class",
      "phase": "regulatory",
      "currentStage": 1,
      "flag": null,
      "stages": [
        { "status": "done", "note": "Met its Phase III primary endpoint in KALUMA (NCT05842954): 97.4% PCR-corrected cure at Day 29 vs 94.0% for artemether–lumefantrine (Coartem), in adults and children ≥10 kg. Company-reported; not yet peer-reviewed. Registry: 1,720 participants, 33 sites, 12 African countries, completed 25 Nov 2025.", "date": "Announced 12 Nov 2025; trial completed 25 Nov 2025", "next": "", "nextDate": "", "source": "Novartis / MMV press releases, 12 Nov 2025; ClinicalTrials.gov NCT05842954", "asOf": "2026-08-22", "sources": ["novartis-kaluma", "mmv-ganlum-phase3", "ctgov-kaluma"] },
        { "status": "idle", "note": "Regulatory submission in preparation following Phase III success; no filing announced as of 15 Oct 2026", "date": "Regulatory submission in preparation", "next": "Dossier submission (SRA pathway)", "nextDate": "TBC", "source": "Novartis announcement, Nov 2025", "asOf": "2026-10-15", "sources": ["novartis-kaluma", "mmv-ganlum-phase3"] },
        { "status": "idle", "note": "Not started", "date": "", "next": "GDG engagement expected alongside regulatory review", "nextDate": "" },
        { "status": "idle", "note": "Not on the WHO PQ EOI list yet (24th malaria EOI, updated 27 Feb 2026, checked)", "date": "", "next": "", "nextDate": "", "source": "WHO PQ EOI list (24th edition)", "asOf": "2026-08-22", "sources": ["who-pq-eoi-malaria-24", "who-pq-fpp"] },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" }
      ],
      "detail": {
        "price": { "value": "TBC", "note": "Pricing not yet public — will be shown once confirmed by manufacturer", "source": "", "confirmedInWriting": false, "asOf": "2026-08-14" },
        "useCase": "Non-artemisinin combination in late-stage development. Novartis presents it as having the potential to combat antimalarial drug resistance; LAUNCH tracks it as a candidate for settings with artemisinin partial resistance and for multiple first-line therapy (MFT) strategies.",
        "access": [
          "Price not public. MMV has said it will be supplied on a \"largely not-for-profit\" basis in low- and middle-income countries (reported Nov 2025).",
          "In Phase III: granules in a sachet, once daily for 3 days with a light meal, for adults and children ≥10 kg. Final product presentation subject to approval."
        ],
        "adoption": [
          "New chemical class (imidazolopiperazine). Safety monitoring after approval will need planning (LAUNCH assessment).",
          "Health-worker training on new regimen"
        ],
        "research": { "lead": "Novartis", "geographies": "12 African countries (KALUMA trial sites)", "timeline": "Phase III complete Nov 2025", "question": "Does it cure infections carrying artemisinin partial-resistance (kelch13) mutations as well as other infections? (KALUMA subgroup not yet published.) Does faster gametocyte clearance reduce infection of mosquitoes? (Not yet measured.)" },
        "country": { "registered": 0, "inGuidelines": 0, "inMft": 0, "forecastDemand": "—" },
        "volume": null,
        "volumeNote": "Pre-launch — no procurement yet",
        "milestones": [
          { "milestone": "Phase III (KALUMA)", "status": "done", "label": "Complete", "date": "12 Nov 2025 (trial completed 25 Nov 2025)", "next": "—", "anticipated": "—", "source": "Novartis / MMV press releases; ClinicalTrials.gov NCT05842954", "sources": ["novartis-kaluma", "mmv-ganlum-phase3", "ctgov-kaluma"] },
          { "milestone": "SRA dossier submission", "status": "prog", "label": "In preparation", "date": "—", "next": "Submission", "anticipated": "TBC", "source": "Novartis announcement, Nov 2025", "sources": ["novartis-kaluma", "mmv-ganlum-phase3"] },
          { "milestone": "WHO GDG engagement", "status": "idle", "label": "Not started", "date": "—", "next": "Pre-submission dialogue", "anticipated": "TBC", "source": "", "sources": ["who-pado-malaria-2025"] },
          { "milestone": "WHO PQ listing", "status": "idle", "label": "Not started", "date": "—", "next": "EOI listing (not on 24th malaria EOI, Feb 2026)", "anticipated": "TBC", "source": "WHO PQ EOI list (24th edition)", "sources": ["who-pq-eoi-malaria-24"] }
        ]
      }
    },
    {
      "id": "alaq",
      "name": "ALAQ",
      "inn": "Artemether–lumefantrine–amodiaquine (triple ACT)",
      "manufacturer": "Fosun Pharma · MORU (FD-TACT)",
      "class": "pipeline",
      "classLabel": "Pipeline · triple ACT",
      "phase": "phase3",
      "currentStage": 0,
      "flag": null,
      "stages": [
        { "status": "prog", "note": "Co-formulated fixed-dose triple ACT in pivotal Phase III (FD-TACT, NCT05951595; started 11 Sep 2025); dose optimisation published 2025; paediatric dispersible tablet in the trial", "date": "Phase III targeted completion 2025–26", "next": "Phase III results, then dossier preparation", "nextDate": "TBC", "source": "MORU / FD-TACT; Clin Pharmacol Ther 2025; WHO PADO malaria, Jun 2025", "asOf": "2026-08-23", "sources": ["clinicaltrials-fd-tact", "cpt-alaq-dose-2025", "who-pado-malaria-2025", "ghit-alaq-fdc"] },
        { "status": "idle", "note": "Not started", "date": "", "next": "Regulatory submission after Phase III results", "nextDate": "TBC", "source": "ClinicalTrials.gov NCT05951595; GHIT Fund project G2022-205", "sources": ["clinicaltrials-fd-tact", "ghit-alaq-fdc"] },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not yet included in WHO PQ Expression of Interest list (24th malaria EOI, updated 27 Feb 2026, checked)", "date": "", "next": "WHO prequalification planned after Phase III", "nextDate": "TBC", "source": "WHO PADO malaria, Jun 2025; WHO PQ EOI list (24th edition)", "asOf": "2026-08-22", "sources": ["who-pq-eoi-malaria-24", "who-pado-malaria-2025", "ghit-alaq-fdc"] },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" },
        { "status": "idle", "note": "Not started", "date": "", "next": "", "nextDate": "" }
      ],
      "detail": {
        "price": { "value": "TBC", "note": "Pricing not yet public — will be shown once confirmed by manufacturer", "source": "", "confirmedInWriting": false, "asOf": "2026-08-14" },
        "useCase": "Triple artemisinin-based combination therapy in clinical development. Its potential future role may include use within treatment-diversification or MFT strategies, subject to clinical results, regulatory assessment, WHO recommendations and country decisions.",
        "access": [
          "Fixed-dose combination developed and made by Fosun Pharma. Pivotal trial (FD-TACT) run by MORU/University of Oxford with MMV and Marubeni, funded by the GHIT Fund.",
          "Fosun Pharma has committed to make it \"accessible and affordable for malaria-endemic countries\". No price published.",
          "Paediatric dispersible tablet (20/120/40 mg) being tested in FD-TACT."
        ],
        "adoption": [
          "Updated treatment guidelines and job aids",
          "Training on a new co-formulated product (same 6-dose, 3-day schedule as AL)."
        ],
        "research": { "lead": "MORU / University of Oxford (FD-TACT), with Fosun Pharma", "geographies": "Rwanda, Uganda, Angola, Nigeria and Thailand (FD-TACT sites named by the GHIT Fund; the registry lists Rwanda so far)", "timeline": "Phase III → 2025–26", "question": "Is fixed-dose ALAQ as effective as AL and ASAQ (28-day cure, FD-TACT), and safe? Adherence outside supervised treatment and use at scale are not yet studied." },
        "country": { "registered": 0, "inGuidelines": 0, "inMft": 0, "forecastDemand": "—" },
        "volume": null,
        "volumeNote": "Pre-launch — no procurement yet",
        "milestones": [
          { "milestone": "Dose-optimization of co-formulation", "status": "done", "label": "Complete", "date": "Published 2025", "next": "—", "anticipated": "—", "source": "Clin Pharmacol Ther (2025)", "sources": ["cpt-alaq-dose-2025"] },
          { "milestone": "Pivotal Phase III (FD-TACT)", "status": "prog", "label": "In progress", "date": "First patient Sep 2025", "next": "Results", "anticipated": "2026", "source": "MORU / FD-TACT", "sources": ["clinicaltrials-fd-tact"] },
          { "milestone": "SRA/WLA submission", "status": "idle", "label": "Not started", "date": "—", "next": "Dossier preparation", "anticipated": "TBC", "source": "" },
          { "milestone": "WHO PQ listing", "status": "idle", "label": "Not started", "date": "—", "next": "EOI listing, then dossier", "anticipated": "TBC", "source": "WHO PADO malaria, Jun 2025", "sources": ["who-pq-eoi-malaria-24", "who-pado-malaria-2025"] }
        ]
      }
    },
    {
      "id": "pyramax",
      "name": "ASPY",
      "inn": "Artesunate–pyronaridine (Pyramax)",
      "manufacturer": "Shin Poong Pharmaceutical · MMV",
      "class": "market",
      "classLabel": "Recommended · underutilized",
      "phase": "access",
      "currentStage": 5,
      "flag": "Adoption is the current access barrier — strongly recommended by WHO since 2022 and on the country access map in 13 countries with a reliable source, but national guideline inclusion remains limited",
      "barrier": "National guideline inclusion is limited",
      "stages": [
        { "status": "done", "note": "Development complete (Shin Poong / MMV co-development)", "date": "", "next": "", "nextDate": "", "source": "MMV", "asOf": "2026-08-14", "sources": ["mmv-pyramax", "mmv-pyramax-pregnancy"] },
        { "status": "done", "note": "EMA positive scientific opinion (Article 58/EU-M4all, 16 Feb 2012); 2025 label update: tablets may be used in the 2nd and 3rd trimesters when the benefit outweighs the risk (EMA opinion 5 Jun 2025; product information updated 6 Aug 2025)", "date": "2012 (label update 2025)", "next": "", "nextDate": "", "source": "EMA EU-M4all opinions table; EMA product information, 6 Aug 2025; MMV, 20 Aug 2025", "asOf": "2026-08-22", "sources": ["ema-pyramax", "mmv-pyramax-pregnancy"] },
        { "status": "done", "note": "Strong recommendation in revised WHO Guidelines for malaria", "date": "2022", "next": "", "nextDate": "", "source": "WHO Guidelines for malaria; MMV", "asOf": "2026-08-14", "sources": ["who-guidelines", "mmv-pyramax"] },
        { "status": "done", "note": "WHO PQ list carries tablets and granules as EMA-Art.-58 alternative listings (refs H-W-2319-2/-3)", "date": "2012–2016", "next": "", "nextDate": "", "source": "WHO PQ list of prequalified medicines (extract 22 Aug 2026)", "asOf": "2026-08-22", "sources": ["who-pq-fpp", "ema-pyramax"] },
        { "status": "prog", "note": "Confirmed in five national registers so far: Tanzania — 2 registrations (TMDA, issued 8 Mar 2022, Registered/Compliant); Nigeria — granules B4-9425 (NAFDAC Greenbook, approved 28 Feb 2024, Active); Rwanda — tablets and granules (Rwanda FDA, 17 Aug 2024, valid); Zambia — tablets ZAMRA-HM-25-239 (11 Jul 2025, Registered/Compliant); Viet Nam — 2 registrations (DAV, first 27 Dec 2013, valid)", "date": "Rolling", "next": "Verify remaining countries against national registers", "nextDate": "TBC", "source": "NAFDAC, TMDA, Rwanda FDA, ZAMRA and DAV registers", "asOf": "2026-10-05", "sources": ["nafdac", "tmda", "rwanda-fda", "zamra", "dav"] },
        { "status": "late", "note": "In national guidelines in 7 countries on the country access map, and in MFT plans in 4 more; each country is cited to a WHO publication or a peer-reviewed paper. Ghana added artesunate–pyronaridine as an alternate first-line ACT in 2022, alongside AS-AQ and AL", "date": "Ghana 2022; WHO policy table 2024", "next": "Country guideline committee reviews", "nextDate": "TBC", "source": "WHO World Malaria Report 2025, Annex 4B (policy as of 2024); WHO MFT implementation guide; peer-reviewed papers, including a Ghana therapeutic-efficacy study (see the country access map)", "asOf": "2026-10-05", "sources": ["who-wmr-annex-4b", "who-mft-guide", "frontiers-ghana-tes", "bmjgh-rwanda-mft", "malariaj-burkina-mft", "malariaj-kenya-mft"] },
        { "status": "prog", "note": "Global Fund procurement 2018–2025: 68 transactions, US$14.5m — modest overall, but US$11.6m of it landed in 2025 (led by Uganda and Burkina Faso), a sharp uptick consistent with early MFT rollouts", "date": "Since 2018", "next": "Verify 2025 surge holds in next quarterly PQR extract", "nextDate": "Q4 2026", "source": "Global Fund PQR Transaction Summary (extract 23 Aug 2026)", "asOf": "2026-08-23", "sources": ["global-fund-pqr"] },
        { "status": "idle", "note": "Routine delivery limited; concentrated in pilot and study settings", "date": "", "next": "", "nextDate": "" }
      ],
      "detail": {
        "price": { "value": "TBC", "note": "Global Fund reference pricing to be displayed once confirmed for release; PQR transaction prices vary by pack presentation", "source": "", "confirmedInWriting": false, "asOf": "2026-08-23" },
        "useCase": "WHO-recommended ACT with verified registration and adoption varying by country. LAUNCH is validating country-level registration, guideline inclusion, MFT positioning, procurement and routine-use information.",
        "access": [
          "On the WHO list of prequalified medicines (tablets and granules), through the EMA EU-M4all (Article 58) route.",
          "Registration confirmed in five national registers so far: Nigeria, Rwanda, Tanzania, Viet Nam and Zambia",
          "Co-developed by Shin Poong and MMV."
        ],
        "adoption": [
          "Guideline inclusion and case-management training",
          "No cold chain (store below 30°C). Once daily for 3 days, with or without food. Not for people with liver disease."
        ],
        "research": { "lead": "MMV and partners", "geographies": "Ghana, Vietnam, Burkina Faso and others (efficacy studies)", "timeline": "Ongoing", "question": "MFT deployment models with artesunate–pyronaridine" },
        "country": { "registered": 2, "inGuidelines": 7, "inMft": 4, "forecastDemand": "TBC" },
        "countries": {
          "status": "verified",
          "note": "Every country listed is cited to a national medicines regulator's own register, a WHO publication or a peer-reviewed paper. Each entry's \"sources\" are ids in data/sources.js and \"checked\" is the date they were verified; \"mft\" says whether an MFT plan is a pilot, planned or national. Countries without such a source are left out and show No data. MMV's product map, meeting slides and news reports are not used. Rule agreed 5 Oct 2026; replaces the illustrative subset.",
          "list": [
            { "iso3": "NGA", "level": "mft", "mft": "planned", "sources": ["who-mft-guide", "nafdac", "who-wmr-annex-4b"], "checked": "2026-10-05", "note": "WHO MFT guide: planned pilot, 40% ASPY in the SMC states" },
            { "iso3": "RWA", "level": "mft", "mft": "national", "sources": ["bmjgh-rwanda-mft", "who-mft-guide", "rwanda-fda"], "checked": "2026-10-05", "note": "ASPY assigned to the western region" },
            { "iso3": "BFA", "level": "mft", "mft": "pilot", "sources": ["malariaj-burkina-mft", "who-wmr-annex-4b"], "checked": "2026-10-05", "note": "Kaya district pilot with ASPY, DHA-PPQ and AL; first-line in national policy" },
            { "iso3": "KEN", "level": "mft", "mft": "pilot", "sources": ["malariaj-kenya-mft"], "checked": "2026-10-05", "note": "Homa Bay pilot, June 2020 to June 2022" },
            { "iso3": "GHA", "level": "guidelines", "sources": ["frontiers-ghana-tes"], "checked": "2026-10-05", "note": "First-line since 2022, alongside AS-AQ and AL; not yet in the WHO 2024 policy table" },
            { "iso3": "VNM", "level": "guidelines", "sources": ["who-wmr-annex-4b", "dav"], "checked": "2026-10-05", "note": "Listed for unconfirmed (untested) P. falciparum" },
            { "iso3": "COD", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "CMR", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "THA", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "KOR", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05", "note": "WHO writes \"PY\"; read as artesunate–pyronaridine" },
            { "iso3": "SSD", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05", "note": "P. vivax treatment only" },
            { "iso3": "TZA", "level": "registered", "sources": ["tmda"], "checked": "2026-10-05" },
            { "iso3": "ZMB", "level": "registered", "sources": ["zamra"], "checked": "2026-10-05" }
          ]
        },
        "journey": [
          { "label": "EMA Article 58 positive opinion", "year": 2012 },
          { "label": "WHO PQ listing (tablets)", "year": 2012 },
          { "label": "Paediatric granules prequalified", "year": 2016 },
          { "label": "WHO strong recommendation", "year": 2022 },
          { "label": "Broad national guideline inclusion", "year": "TBC" }
        ],
        "volume": {
          "total": "68 transactions · US$14.5m (2018–2025)",
          "period": "Global Fund PQR, 2018–2025 · US$11.6m in 2025 · top buyers Uganda, Burkina Faso, Ghana",
          "split": [
            { "channel": "Global Fund (PQR-recorded)", "pct": 100 }
          ],
          "source": "Global Fund PQR Transaction Summary, extract 23 Aug 2026 — sourcing/staging/procurement_transactions.csv. Covers Global Fund-financed procurement only; US PMI data unavailable post-2025 (GHSC-PSM dataset offline). Recent quarters incomplete due to PQR reporting lag.",
          "byPresentation": [
            { "label": "60/180 mg tablets · pack of 90", "transactions": 43, "packs": 542233, "courses": null },
            { "label": "20/60 mg granules · 90 sachets", "transactions": 25, "packs": 397878, "courses": null }
          ],
          "coursesRule": "Treatment courses are not estimated: the Global Fund's product names for ASPY do not state how many tablets or sachets make one course, and the number depends on body weight.",
          "sources": [
            "global-fund-pqr"
          ]
        },
        "milestones": [
          { "milestone": "SRA approval (EMA Art. 58)", "status": "done", "label": "Complete", "date": "16 Feb 2012", "next": "—", "anticipated": "—", "source": "EMA EU-M4all opinions table", "sources": ["ema-pyramax", "ema"] },
          { "milestone": "WHO PQ listing", "status": "done", "label": "Complete", "date": "2012–2016", "next": "—", "anticipated": "—", "source": "WHO PQ list", "sources": ["who-pq-fpp"] },
          { "milestone": "WHO recommendation (strong)", "status": "done", "label": "Complete", "date": "2022", "next": "—", "anticipated": "—", "source": "WHO Guidelines for malaria", "sources": ["who-guidelines"] },
          { "milestone": "Label update — pregnancy", "status": "done", "label": "Complete", "date": "EMA outcome 5 Jun 2025", "next": "—", "anticipated": "—", "source": "EMA EU-M4all opinions table; EMA product information, 6 Aug 2025; MMV, 20 Aug 2025", "sources": ["ema-pyramax", "mmv-pyramax-pregnancy"] },
          { "milestone": "Country registrations", "status": "prog", "label": "5 countries register-confirmed", "date": "Rolling (VNM 2013, TZA 2022, NGA 2024, RWA 2024, ZMB 2025)", "next": "Verify remaining countries against national registers", "anticipated": "TBC", "source": "NAFDAC, TMDA, Rwanda FDA, ZAMRA and DAV registers (5 Oct 2026)", "sources": ["nafdac", "tmda", "rwanda-fda", "zamra", "dav"] },
          { "milestone": "National guideline inclusion", "status": "late", "label": "7 countries, plus 4 with MFT plans", "date": "Ghana 2022; WHO policy table 2024", "next": "Committee reviews in other endemic countries", "anticipated": "TBC", "source": "WHO World Malaria Report 2025, Annex 4B (policy as of 2024); WHO MFT implementation guide; peer-reviewed papers (see the country access map)", "sources": ["who-wmr-annex-4b", "who-mft-guide", "frontiers-ghana-tes", "bmjgh-rwanda-mft", "malariaj-burkina-mft", "malariaj-kenya-mft"] },
          { "milestone": "Procurement scale-up", "status": "prog", "label": "US$14.5m, 68 transactions (GF, to 2025)", "date": "US$11.6m in 2025", "next": "Verify surge in next PQR extract", "anticipated": "Q4 2026", "source": "Global Fund PQR (extract 23 Aug 2026)", "sources": ["global-fund-pqr"] }
        ]
      }
    },
    {
      "id": "dhappq",
      "name": "DHA–PPQ",
      "inn": "Dihydroartemisinin–piperaquine",
      "manufacturer": "Alfasigma (Eurartesim) · Guilin · Beijing Holley (PQ'd suppliers)",
      "class": "market",
      "classLabel": "Recommended · underutilized",
      "phase": "access",
      "currentStage": 6,
      "flag": "Procurement is the current access barrier — 0.9–4.5% of the value of all antimalarial medicines the Global Fund ordered each year in 2022–24, despite a WHO recommendation dating to 2010, though 2025 orders surged (PQR, reporting still incomplete)",
      "barrier": "Only 0.9–4.5% of Global Fund antimalarial orders by value, 2022–24",
      "stages": [
        { "status": "done", "note": "Development complete", "date": "", "next": "", "nextDate": "", "source": "MMV", "asOf": "2026-08-14", "sources": ["mmv-dhappq"] },
        { "status": "done", "note": "EMA approval (Eurartesim)", "date": "2011", "next": "", "nextDate": "", "source": "EMA register", "asOf": "2026-08-14", "sources": ["ema-eurartesim"] },
        { "status": "done", "note": "WHO-recommended ACT for uncomplicated malaria — added as the fifth recommended ACT in the 2010 second-edition treatment guidelines; reaffirmed 2015", "date": "2010 guidelines (2nd ed.)", "next": "", "nextDate": "", "source": "WHO Guidelines for the treatment of malaria, 2nd ed. (2010); WHO news, 10 Dec 2010", "asOf": "2026-08-23", "sources": ["who-guidelines-2010", "who-guidelines"] },
        { "status": "done", "note": "Nine WHO-prequalified presentations from three companies: Alfasigma (2015; requalified 8 and 20 Jan 2025), Guilin (2019–2020, including 3 dispersible) and Beijing Holley (2023). WHO records list one site as the only dihydroartemisinin ingredient source for 8 of the 9.", "date": "2015–2023; requalified Jan 2025", "next": "", "nextDate": "", "source": "WHO PQ list of prequalified medicines (extract 22 Aug 2026)", "asOf": "2026-08-22", "sources": ["who-pq-fpp", "whopar-ma093", "whopar-ma140"] },
        { "status": "done", "note": "Confirmed in six national registers so far: Nigeria, Rwanda, Tanzania, Viet Nam, Zambia and Zimbabwe. Register detail: Tanzania — 10 presentations across four manufacturers (Guilin D-ARTEPP incl. paediatric dispersible, KBN-Zhejiang Duo-Cotecxin, Ajanta Ridmal), all Registered/Compliant; Nigeria — 47 presentations, of which 25 are active and 22 have lapsed (registrations not being maintained, itself an underuse signal)", "date": "Rolling", "next": "Verify remaining countries against national registers", "nextDate": "TBC", "source": "NAFDAC, Rwanda FDA, TMDA, DAV, ZAMRA and MCAZ registers (see the country access map); NAFDAC Greenbook + TMDA IMIS2 extracts 31 Aug 2026", "asOf": "2026-10-05", "sources": ["nafdac", "rwanda-fda", "tmda", "dav", "zamra", "mcaz"] },
        { "status": "prog", "note": "In national guidelines in 9 countries on the country access map, and in MFT plans in 4 more; each country is cited to a WHO publication or a peer-reviewed paper", "date": "WHO policy table 2024", "next": "MFT strategy decisions", "nextDate": "TBC", "source": "WHO World Malaria Report 2025, Annex 4B (policy as of 2024); WHO MFT implementation guide; peer-reviewed papers (see the country access map)", "asOf": "2026-10-05", "sources": ["who-wmr-annex-4b", "who-mft-guide", "frontiers-ghana-tes", "bmjgh-rwanda-mft", "malariaj-burkina-mft", "malariaj-kenya-mft"] },
        { "status": "late", "note": "Global Fund orders go back to 2008 (US$41.5m over 234 transactions, 2008–2026), but have stayed small: 0.9–4.5% of the value of all antimalarial medicines the Global Fund ordered each year in 2022–24 (4.4% in 2022, 0.9% in 2023, 4.5% in 2024, by order date). The timeline counts from WHO prequalification in 2015. 2025 shows a sharp uptick (US$15.3m, led by Uganda, Madagascar, Mozambique) that needs confirming as reporting completes", "date": "Since 2008", "next": "Verify 2025 surge holds in next quarterly PQR extract", "nextDate": "Q4 2026", "source": "Global Fund PQR Transaction Summary (extract 23 Aug 2026)", "asOf": "2026-08-23", "sources": ["global-fund-pqr"] },
        { "status": "prog", "note": "National policy and Global Fund procurement vary substantially between countries", "date": "", "next": "", "nextDate": "", "source": "WHO World Malaria Report 2025, Annex 4B; Global Fund PQR Transaction Summary", "asOf": "2026-08-14", "sources": ["global-fund-pqr", "who-wmr-annex-4b"] }
      ],
      "detail": {
        "price": { "value": "TBC", "note": "Pooled procurement reference pricing to be displayed once confirmed for release; PQR median pack price ≈ US$1.70 across presentations (indicative only — pack sizes vary)", "source": "", "confirmedInWriting": false, "asOf": "2026-08-23" },
        "useCase": "WHO-recommended ACT used for treatment in a range of settings and potentially relevant to MFT strategies. Chemoprevention and mass drug administration are separate uses, each with its own indications, formulations, evidence and policy pathway.",
        "access": [
          "Nine WHO-prequalified presentations from three companies: Alfasigma (2), Guilin (6, including 3 dispersible) and Beijing Holley (1)."
        ],
        "adoption": [
          "Prolongs the QT interval. Not for people with QT prolongation or on QT-prolonging medicines (WHO; EU label). The EU label advises an ECG during treatment; WHO says one is not needed before prescribing.",
          "Standard ACT training, plus food timing and the QT contraindications."
        ],
        "research": { "lead": "Multiple academic consortia", "geographies": "Ghana, Mozambique, SE Asia (efficacy and MFT studies)", "timeline": "Ongoing", "question": "MFT deployment (simultaneous, cycling or rotation) and resistance impact" },
        "country": { "registered": 2, "inGuidelines": 9, "inMft": 4, "forecastDemand": "TBC" },
        "countries": {
          "status": "verified",
          "note": "Every country listed is cited to a national medicines regulator's own register, a WHO publication or a peer-reviewed paper. Each entry's \"sources\" are ids in data/sources.js and \"checked\" is the date they were verified; \"mft\" says whether an MFT plan is a pilot, planned or national. Countries without such a source are left out and show No data. MMV's product map, meeting slides and news reports are not used. Rule agreed 5 Oct 2026; replaces the illustrative subset.",
          "list": [
            { "iso3": "NGA", "level": "mft", "mft": "planned", "sources": ["who-mft-guide", "nafdac", "who-wmr-annex-4b"], "checked": "2026-10-05", "note": "WHO MFT guide: planned pilot, 40% DHA-PPQ in the SMC states" },
            { "iso3": "RWA", "level": "mft", "mft": "national", "sources": ["bmjgh-rwanda-mft", "who-mft-guide", "rwanda-fda"], "checked": "2026-10-05", "note": "DHA-PPQ assigned to the eastern and central regions" },
            { "iso3": "BFA", "level": "mft", "mft": "pilot", "sources": ["malariaj-burkina-mft", "who-wmr-annex-4b"], "checked": "2026-10-05", "note": "Kaya district pilot with ASPY, DHA-PPQ and AL; first-line in national policy" },
            { "iso3": "KEN", "level": "mft", "mft": "pilot", "sources": ["malariaj-kenya-mft"], "checked": "2026-10-05", "note": "Homa Bay pilot, June 2020 to June 2022" },
            { "iso3": "TZA", "level": "guidelines", "sources": ["tmda", "who-wmr-annex-4b"], "checked": "2026-10-05", "note": "Mainland policy; Zanzibar's own row does not list it" },
            { "iso3": "VNM", "level": "guidelines", "sources": ["who-wmr-annex-4b", "dav"], "checked": "2026-10-05" },
            { "iso3": "THA", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "IDN", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "GHA", "level": "guidelines", "sources": ["who-wmr-annex-4b", "frontiers-ghana-tes"], "checked": "2026-10-05", "note": "Listed for untested P. falciparum and P. vivax; second-line nationally" },
            { "iso3": "AGO", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "CMR", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "GAB", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05" },
            { "iso3": "PNG", "level": "guidelines", "sources": ["who-wmr-annex-4b"], "checked": "2026-10-05", "note": "Severe malaria only" },
            { "iso3": "ZMB", "level": "registered", "sources": ["zamra"], "checked": "2026-10-05" },
            { "iso3": "ZWE", "level": "registered", "sources": ["mcaz"], "checked": "2026-10-05" }
          ]
        },
        "journey": [
          { "label": "WHO recommendation", "year": 2010 },
          { "label": "EMA approval (Eurartesim)", "year": 2011 },
          { "label": "WHO PQ listing", "year": 2015 },
          { "label": "Broad procurement uptake", "year": "TBC" }
        ],
        "volume": {
          "total": "234 transactions · US$41.5m (2008–2026)",
          "period": "Global Fund PQR, 2008–2026 · US$15.3m in 2025 · top buyers Uganda, Madagascar, Mozambique",
          "split": [
            { "channel": "Global Fund (PQR-recorded)", "pct": 100 }
          ],
          "source": "Global Fund PQR Transaction Summary, extract 23 Aug 2026 — sourcing/staging/procurement_transactions.csv. Covers Global Fund-financed procurement only; US PMI data unavailable post-2025 (GHSC-PSM dataset offline). Recent quarters incomplete due to PQR reporting lag.",
          "byPresentation": [
            { "label": "40/320 mg tablets · blister of 9", "transactions": 69, "packs": 6400111, "courses": 6400111 },
            { "label": "40/320 mg dispersible tablets · blister of 3", "transactions": 15, "packs": 2711497, "courses": null },
            { "label": "40/320 mg dispersible tablets · box of 2 blisters of 3", "transactions": 11, "packs": 427750, "courses": null },
            { "label": "20/160 mg dispersible tablets · box of 25 blisters of 3", "transactions": 25, "packs": 334390, "courses": 8359750 },
            { "label": "40/320 mg tablets · box of 25 blisters of 9", "transactions": 19, "packs": 323694, "courses": 8092350 },
            { "label": "20/160 mg dispersible tablets · box of 2 blisters of 3", "transactions": 25, "packs": 315009, "courses": 630018 },
            { "label": "40/320 mg tablets · blister of 3", "transactions": 21, "packs": 305842, "courses": 305842 },
            { "label": "40/320 mg tablets · blister of 6", "transactions": 27, "packs": 205708, "courses": 205708 },
            { "label": "40/320 mg tablets · recorded as 3 per course, in a blister of 8", "transactions": 7, "packs": 166193, "courses": null },
            { "label": "20/160 mg dispersible tablets · blister of 3", "transactions": 3, "packs": 134728, "courses": 134728 },
            { "label": "20/160 mg tablets · blister of 3", "transactions": 9, "packs": 95290, "courses": 95290 },
            { "label": "40/320 mg dispersible tablets · box of 25 blisters of 3", "transactions": 3, "packs": 72827, "courses": null }
          ],
          "coursesRule": "Treatment courses are estimated only where the Global Fund's product name states the tablets in one course (\"40mg+320mg - 9\" is 9 tablets): courses = tablets in the pack ÷ tablets per course. Packs whose name does not state it, or does not divide evenly, are not estimated.",
          "sources": [
            "global-fund-pqr"
          ]
        },
        "milestones": [
          { "milestone": "WHO recommendation", "status": "done", "label": "Complete", "date": "2010 (2nd ed.; reaffirmed 2015)", "next": "—", "anticipated": "—", "source": "WHO Guidelines for the treatment of malaria, 2nd ed. (2010)", "sources": ["who-guidelines-2010", "who-guidelines"] },
          { "milestone": "SRA approval (EMA, Eurartesim)", "status": "done", "label": "Complete", "date": "2011", "next": "—", "anticipated": "—", "source": "EMA register", "sources": ["ema-eurartesim"] },
          { "milestone": "WHO PQ listing (Eurartesim)", "status": "done", "label": "Complete", "date": "9 Oct 2015", "next": "—", "anticipated": "—", "source": "WHO PQ list", "sources": ["who-pq-fpp", "whopar-ma093"] },
          { "milestone": "WHO PQ requalification", "status": "done", "label": "Complete", "date": "20 Jan 2025", "next": "—", "anticipated": "—", "source": "WHO PQ list", "sources": ["whopar-ma093"] },
          { "milestone": "Additional PQ'd suppliers", "status": "done", "label": "9 presentations · 3 makers", "date": "2015–2023", "next": "—", "anticipated": "—", "source": "WHO PQ list (extract 22 Aug 2026)", "sources": ["who-pq-fpp"] },
          { "milestone": "Register detail: Tanzania and Nigeria", "status": "done", "label": "Tanzania: 10 registered presentations, all compliant · Nigeria: 47 registered presentations, 25 active, 22 lapsed", "date": "Extracts 31 Aug 2026", "next": "Further countries", "anticipated": "TBC", "source": "NAFDAC Greenbook; TMDA IMIS2", "sources": ["nafdac", "tmda"] },
          { "milestone": "National guideline inclusion", "status": "prog", "label": "9 countries, plus 4 with MFT plans", "date": "WHO policy table 2024", "next": "MFT strategy decisions", "anticipated": "TBC", "source": "WHO World Malaria Report 2025, Annex 4B (policy as of 2024); WHO MFT implementation guide; peer-reviewed papers (see the country access map)", "sources": ["who-wmr-annex-4b", "who-mft-guide", "frontiers-ghana-tes", "bmjgh-rwanda-mft", "malariaj-burkina-mft", "malariaj-kenya-mft"] },
          { "milestone": "Procurement scale-up", "status": "late", "label": "US$41.5m since 2008", "date": "US$15.3m in 2025", "next": "Verify surge in next PQR extract", "anticipated": "Q4 2026", "source": "Global Fund PQR (extract 23 Aug 2026)", "sources": ["global-fund-pqr"] }
        ]
      }
    }
  ]
}
